Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Leila Amini(Humboldt-Universität zu Berlin), Mohamed Abou‐El‐Enein(University of Southern California), Carlos A. Ramos(Methodist Hospital), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Nirali N. Shah(National Institutes of Health), Shannon L. Maude(Children's Hospital of Philadelphia), Renier J. Brentjens(Roswell Park Comprehensive Cancer Center), Sara Silbert(National Institutes of Health), Craig S. Sauter(Memorial Sloan Kettering Cancer Center)
Cited by 324
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
|Nature Reviews Clinical Oncology|2019|1.4k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782